Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30372
Diagnostic Evaluation of Urinary Angiogenin (ANG) and Clusterin (CLU) as Biomarker for Bladder Cancer

Authors: Marwa I. Shabayek, Ola A. Said, Hanan A. Attaia, Heba A. Awida

Abstract:

Bladder carcinoma is an important worldwide health problem. Both cystoscopy and urine cytology used in detecting bladder cancer suffer from drawbacks where cystoscopy is an invasive method and urine cytology shows low sensitivity in low grade tumors. This study validates easier and less time-consuming techniques to evaluate the value of combined use of angiogenin and clusterin in comparison and combination with voided urine cytology in the detection of bladder cancer patients. This study includes malignant (bladder cancer patients, n= 50), benign (n=20) and healthy (n=20) groups. The studied groups were subjected to cystoscopic examination, detection of bilharzial antibodies, urine cytology, and estimation of urinary angiogenin and clusterin by ELISA. The overall sensitivity and specificity were 66% and 75% for angiogenin, 70% and 82.5% for clusterin and 46% and 80% for voided urine cytology. Combined sensitivity of angiogenin and clusterin with urine cytology increased from 82 to 88%. 

Keywords: Cytology, angiogenin, bladder cancer, clusterin

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1089070

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1487

References:


[1] American Cancer Society: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013.
[2] S. Zaghloul, Bladder cancer and schistosomiasis, Journal of the Egyptian National Cancer Institute (2012) 24, 151–159.
[3] S. Eissa, M. Shabayek, M. Ismail et al., Diagnostic Evaluation of Apoptosis Inhibitory Gene and Tissue Inhibitor Matrix Metalloproteinase-2 in Patients with Bladder Cancer, IUBMB Life (2010) 62(5): 394–399, May.
[4] V. Urquidi, S. Goodison, J. Kim, et al., Vascular enothelail growth factor, carbonic anhydrase 9, and Angiogenin as urinary biomarkers for bladder cancer detection, Urology (2012) May ; 79(5): 1185.e1–1185.e6.
[5] A. Mitra, Urine Cytologic Analysis: Special Techniques for Bladder Cancer Detection, Connection (2010) 169-177.
[6] A.Yafi, F. Brimo, M. Auger, et al., Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer, Urologic Oncology: Seminars and Original Investigations (2013) 1–6.
[7] L. Budman, W. Kassouf, JR. Steinberg, Biomarkers for detection and surveillance of bladder cancer, Canidian Urological Association Journal (2008) 2:212–21.
[8] S. Li, G. Hu, Angiogenin-mediated rRNA transcription in cancer and neurodegeneration, Int J Biochem Mol Biol (2010) 1(1):26-35.
[9] S. Eissa, M. Swellam, RA. Labib, et al., A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot, Journal of Urology (2009) Mar; 181(3):1353-60.
[10] M. Hazzaa, M. Elashry, K. Afifi, Clusterin as a Diagnostic and Prognostic Marker for Transitional Cell Carcinoma of the Bladder, Pathology and Oncology Research (2010) 16(1): 101-109
[11] H. Miyake, I. Hara, M. Gleave et al., Protection of androgen dependent human prostate cancer cells from oxidative stressinduced DNA damage by overexpression of clusterin and its modulation by androgen, Prostate (2004) 61:318–323.
[12] M. Redondo, E.Villar, J. Torres-Muñoz et al., Overexpression of Clusterin in human breast carcinoma, American journal of Pathology (2000) 157: 393–399.
[13] L. July, E. Beraldi, A. So et al., Nucleotide-based therapies targeting clusterin chemosensitized human lung adenocarcinoma cells both in vitro and in vivo, Molecular Cancer Therapeutics (2004) 3:223–232.
[14] S. Pucci, E. Bonanno, F. Pichiorri et al., Modulation of different clusterin isoforms in human colon tumorigenesis, Oncogenes (2004) 23:2298–2304.
[15] S. Krüger, A. Mahnken, I. Kausch et al., Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma, Urology (2006) 67(1):105–109.
[16] L. Zhang, W. Ying, Y. Mao, Loss of clusterin both in serum and tissue correlates with the tumorigenesis of oesophageal squamous cell carcinoma via proteomic approaches, World Journal of Gastroenterology (2003) 9:650–654.
[17] M. Scaltriti, M. Brausi, A. Amorosi, Clusterin (SGP-2, APOJ) expression is downregulated in low- and high-grade human prostate cancer, International Journal of Cancer (2004) 108:23–30.
[18] M. Xie, Y. Motoo, S. Su et al., Expression of clusterin in human pancreatic cancer, Pancreas (2002) 25:234–238.
[19] American Joint Committee on Cancer. AJCC Cancer Staging Manual. Urinary Bladder. 7th ed. New York, NY: Springer (2010) 497-502.
[20] Y.Yang, M. Sun, L. Wang et al., HIFs, Angiogenesis, and Cancer, Journal of Cellular Biochemistry (2013) 114:967–974.
[21] P. Wong, T. Ulyanova, D. Organisciak et al., Expression of multiple forms of clusterin during light-induced retinal degeneration. Current Eye Research (2001) 23:157–165.
[22] I. Trougakso, A. So, B. Jansen et al., Silencing expression of the clusterin / apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress, Cancer Research (2004) 64:1834–1842.
[23] K. Leskov, D. Klokov, J. Li et al., Synthesis and functional analyses of nuclear clusterin, a cell death protein, Journal of Biological Chemistry (2003) 278:11590–11600.
[24] D. Stejskal, R. Fiala, Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer, Neoplasma (2006) 53(4):343–346.
[25] N. Kim, J. Yoo, J. Han et al., Human nuclear clusterin mediates apoptosis by interacting with bcl-xl through c-terminal coiled coil domain, Journal of Cellular Physiology (2012) 227: 1157–1167.
[26] H. Miyake, M. Gleave, S. Kamidono et al., Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence, Urology (2002) 50:150–154.